ClinicalTrials.gg
CompletedNCT07944768Updated Nov 18, 2026

Optimal Induction Agent in Hemodynamically Unstable Patients Undergoing Emergency Surgery: A Comparative Study Between Ketamine and Etomidate With or Without Midazolam

An interventional study of Ketamine and Etomidate in Hemodynamically Unstable Patients, Emergency Surgery and Ketamine, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Jul 2024, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This work aimed to assess the hemodynamic effects of ketamine versus etomidate with or without midazolam as induction agents in patients undergoing emergency surgery.

Read the detailed description

Hemodynamic instability is a frequent and critical challenge in individuals undergoing emergency surgery. The induction of general anesthesia in such patients carries a significant risk of cardiovascular compromise, including hypotension, reduced cardiac output, and peri-induction circulatory collapse.

Etomidate has long been preferred for unstable patients because it produces minimal myocardial depression and preserves sympathetic tone, resulting in comparatively stable blood pressure (BP) and heart rate (HR).

Ketamine, a dissociative anesthetic and NMDA receptor antagonist, has a distinctive hemodynamic profile characterized by indirect sympathomimetic stimulation, leading to increased HR, BP, and cardiac output through enhanced catecholamine activity.

Midazolam, a short-acting benzodiazepine, is frequently co-administered with induction agents to enhance sedation and provide amnesia.

02

Conditions studied

  • Hemodynamically Unstable Patients
  • Emergency Surgery
  • Ketamine
  • Etomidate
  • Midazolam
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 535 studies on the registry; 173 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years.
  • Both sexes.
  • Patients who were underwent emergency surgery with pre-induction hemodynamic instability [mean arterial pressure (MAP) \<65 mmHg, systolic blood pressure (SBP) \<90 mmHg, or vasopressor use].

Exclusion criteria

Exclusion Criteria:

  • History of to any of the study medications.
  • Known primary or secondary adrenal insufficiency.
  • Cardiac arrest prior to anesthetic induction.
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Group K

    Patients received intravenous ketamine 2 mg/kg.

    Drug: Ketamine

  • Experimental
    Group E

    Patients received etomidate 0.3 mg/kg.

    Drug: Etomidate

  • Experimental
    Group KM

    Patients received ketamine 1.5 mg/kg and midazolam 2 mg.

    Drug: Ketamine + Midazolam

  • Experimental
    Group EM

    Patients received etomidate 0.2 mg/kg and midazolam 2 mg.

    Drug: Etomidate + Midazolam

Interventions

  • Patients received intravenous ketamine 2 mg/kg.

  • Patients received etomidate 0.3 mg/kg.

  • DrugKetamine + Midazolam

    Drug pages: Ketamine · Midazolam

    Patients received ketamine 1.5 mg/kg and midazolam 2 mg.

  • DrugEtomidate + Midazolam

    Patients received etomidate 0.2 mg/kg and midazolam 2 mg.

06

What researchers measure

Primary outcomes

  1. Mean arterial pressure at 10 minutes

    Mean arterial pressure was noted before induction and at 1, 3, 5, and 10 minutes following induction.

    Time frame: 10 minutes following induction.

Secondary outcomes

  1. Mean arterial pressure at 15 minutes

    Mean arterial pressure was noted before induction and at 1, 3, 5, 10 and 15 minutes following induction.

    Time frame: 15 minutes following induction.

  2. Mean arterial pressure at 5 minutes

    Mean arterial pressure was noted before induction and at 1, 3, 5, 10 and 15 minutes following induction.

    Time frame: 5 minutes following induction.

07

Study locations

1 site
  • Al-Azhar University
    Damietta, 35527, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Feb 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Jul 1, 2024
Primary completionActual
Feb 1, 2025
CompletionActual
Feb 1, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944768
Responsible party
Mahmoud Gaballah Montaser (Professor of Anesthesia, Intensive Care, and Pain Medicine, Faculty of Medicine, Al-Azhar University, Damietta, Egypt., Al-Azhar University) — Principal investigator
First posted
Nov 18, 2026
Start date
Jul 1, 2024
Primary completion
Feb 1, 2025
Completion
Feb 1, 2025
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Etomidate · Midazolam

Start the discussion